[OH-].[Na+].[CH2:3]([OH:17])[C@@H:4]([OH:16])[C@@H:5]([OH:15])[C@H:6]([OH:14])[C@@H:7]([OH:13])[CH:8]([OH:12])[C:9]([O-:11])=[O:10].[CH2:18]([OH:32])[C@@H:19]([OH:31])[C@@H:20]([OH:30])[C@H:21]([OH:29])[C@@H:22]([OH:28])[CH:23]([OH:27])[C:24]([O-:26])=[O:25].[Ca+2:33].C([O-])(=O)C>>[CH2:3]([OH:17])[C@@H:4]([OH:16])[C@@H:5]([OH:15])[C@H:6]([OH:14])[C@@H:7]([OH:13])[CH:8]([OH:12])[C:9]([O-:11])=[O:10].[CH2:18]([OH:32])[C@@H:19]([OH:31])[C@@H:20]([OH:30])[C@H:21]([OH:29])[C@@H:22]([OH:28])[CH:23]([OH:27])[C:24]([O-:26])=[O:25].[Ca+2:33]This description is for labeling the liposomes with “BMEDA” because the 186Re-“BMEDA” complex produced the higher labeling efficiency and stability. “BMEDA” was synthesized using a modification of a procedure described by Corbin et al. in “Preparation and properties of tripodal and linear tetradentate N,S-donor ligands and their complexes containing the MoO22+ core” Inorganica Chimica Acta. 1984; 90:41-51. First, a 0.17 M glucoheptonate-0.1 M acetate solution was prepared and the pH adjusted to 5.0 with 5 M NaOH. Next, the “BMEDA” solution was prepared by pipetting 4.5 mg of “BMEDA” (4.5 μl) to a new vial and adding 2.1 ml of the glucoheptonate-acetate solution. After flushing the “BMEDA”-glucoheptonate-acetate solution with N2 gas for 20 min, the vial was sealed. The solution was stirred at 25° C. for 40 min. Next, 30 mg of SnCl2.2H2O was dissolved by adding with 2 drops of concentrated HCl in a new vial and 2.0 ml of sterile water added.